Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

Participation Requirements

• Sex:

  ALL

• Eligible Ages:

  50 and up

Participation Criteria

Key Inclusion Criteria:

* Age ≥ 50 years
* Have the capacity to consent on his/her own behalf
* Able to successfully and independently complete at least one self-scanning session on the Home OCT device located at the enrolling clinical site
* Willing to perform once daily Home OCT monitoring tests for 2 years without significant interruption (such as travel of more than 14 days)
* Best corrected E-ETDRS visual acuity ≥24 ETDRS letters (approximately 20/320 or better (Snellen))
* Previously untreated, active macular neovascularization (MNV) lesion (i.e., any intraretinal or subretinal fluid within the center 3x3 mm area on OCT) secondary to age-related macular degeneration
* ≥ 1 intermediate drusen (\>63 microns) in either eye OR late AMD (MNV or macular atrophy) in the contralateral eye

Key Exclusion Criteria for Study Eye:

* Previous treatment for MNV (intravitreal injection of any anti-VEGF or anti-VEGF/anti-Ang2 agent, or any other AMD therapy)
* Prior treatment with intravitreal injection of any anti-VEGF or anti-VEGF/anti-Ang2 agent or with macular laser for any indication
* Treatment with intravitreal corticosteroids within the last 6 months
* Any condition that may preclude adequate imaging of the macula (e.g., dense cataract or other media opacity, severe ptosis)
* MNV due to other causes, such as ocular histoplasmosis, central serous choroidopathy, or pathologic myopia